Literature DB >> 35615063

Molecular Mechanisms in the Genesis of Seizures and Epilepsy Associated With Viral Infection.

Wolfgang Löscher1,2, Charles L Howe3,4.   

Abstract

Seizures are a common presenting symptom during viral infections of the central nervous system (CNS) and can occur during the initial phase of infection ("early" or acute symptomatic seizures), after recovery ("late" or spontaneous seizures, indicating the development of acquired epilepsy), or both. The development of acute and delayed seizures may have shared as well as unique pathogenic mechanisms and prognostic implications. Based on an extensive review of the literature, we present an overview of viruses that are associated with early and late seizures in humans. We then describe potential pathophysiologic mechanisms underlying ictogenesis and epileptogenesis, including routes of neuroinvasion, viral control and clearance, systemic inflammation, alterations of the blood-brain barrier, neuroinflammation, and inflammation-induced molecular reorganization of synapses and neural circuits. We provide clinical and animal model findings to highlight commonalities and differences in these processes across various neurotropic or neuropathogenic viruses, including herpesviruses, SARS-CoV-2, flaviviruses, and picornaviruses. In addition, we extensively review the literature regarding Theiler's murine encephalomyelitis virus (TMEV). This picornavirus, although not pathogenic for humans, is possibly the best-characterized model for understanding the molecular mechanisms that drive seizures, epilepsy, and hippocampal damage during viral infection. An enhanced understanding of these mechanisms derived from the TMEV model may lead to novel therapeutic interventions that interfere with ictogenesis and epileptogenesis, even within non-infectious contexts.
Copyright © 2022 Löscher and Howe.

Entities:  

Keywords:  SARS-CoV-2; blood-brain barrier; flaviruses; herpesviruses; hippocampal damage; neuroinflammation; picornaviruses; status epilepticus

Year:  2022        PMID: 35615063      PMCID: PMC9125338          DOI: 10.3389/fnmol.2022.870868

Source DB:  PubMed          Journal:  Front Mol Neurosci        ISSN: 1662-5099            Impact factor:   6.261


  380 in total

1.  Lassa fever encephalopathy: clinical and laboratory findings.

Authors:  D Cummins; D Bennett; S P Fisher-Hoch; B Farrar; S J Machin; J B McCormick
Journal:  J Trop Med Hyg       Date:  1992-06

Review 2.  High Mobility Group Box 1 is a novel pathogenic factor and a mechanistic biomarker for epilepsy.

Authors:  Teresa Ravizza; Gaetano Terrone; Alessia Salamone; Federica Frigerio; Silvia Balosso; Daniel J Antoine; Annamaria Vezzani
Journal:  Brain Behav Immun       Date:  2017-10-13       Impact factor: 7.217

Review 3.  Tickets to the brain: role of CCR2 and CX3CR1 in myeloid cell entry in the CNS.

Authors:  Marco Prinz; Josef Priller
Journal:  J Neuroimmunol       Date:  2010-05-31       Impact factor: 3.478

4.  Post-acute neurological consequences of COVID-19: an unequal burden.

Authors:  LaShyra T Nolen; Shibani S Mukerji; Nicte I Mejia
Journal:  Nat Med       Date:  2022-01       Impact factor: 87.241

Review 5.  Astrocytes: biology and pathology.

Authors:  Michael V Sofroniew; Harry V Vinters
Journal:  Acta Neuropathol       Date:  2009-12-10       Impact factor: 17.088

6.  Anti-epileptogenic and Anti-convulsive Effects of Fingolimod in Experimental Temporal Lobe Epilepsy.

Authors:  Julika Pitsch; Julia C Kuehn; Vadym Gnatkovsky; Johannes Alexander Müller; Karen M J van Loo; Marco de Curtis; Hartmut Vatter; Susanne Schoch; Christian E Elger; Albert J Becker
Journal:  Mol Neurobiol       Date:  2018-06-22       Impact factor: 5.590

Review 7.  Evaluating microglial phenotypes using single-cell technologies.

Authors:  Roman Sankowski; Gianni Monaco; Marco Prinz
Journal:  Trends Neurosci       Date:  2021-12-04       Impact factor: 13.837

Review 8.  COVID-19 and possible links with Parkinson's disease and parkinsonism: from bench to bedside.

Authors:  David Sulzer; Angelo Antonini; Valentina Leta; Anna Nordvig; Richard J Smeyne; James E Goldman; Osama Al-Dalahmah; Luigi Zecca; Alessandro Sette; Luigi Bubacco; Olimpia Meucci; Elena Moro; Ashley S Harms; Yaqian Xu; Stanley Fahn; K Ray Chaudhuri
Journal:  NPJ Parkinsons Dis       Date:  2020-08-20

Review 9.  TNF signaling inhibition in the CNS: implications for normal brain function and neurodegenerative disease.

Authors:  Melissa K McCoy; Malú G Tansey
Journal:  J Neuroinflammation       Date:  2008-10-17       Impact factor: 8.322

Review 10.  How does the COVID-19 cause seizure and epilepsy in patients? The potential mechanisms.

Authors:  Farnaz Nikbakht; Ali Mohammadkhanizadeh; Ekram Mohammadi
Journal:  Mult Scler Relat Disord       Date:  2020-09-28       Impact factor: 4.339

View more
  1 in total

1.  Brain-Derived Neurotrophic Factor Inhibits the Function of Cation-Chloride Cotransporter in a Mouse Model of Viral Infection-Induced Epilepsy.

Authors:  Dipan C Patel; Emily G Thompson; Harald Sontheimer
Journal:  Front Cell Dev Biol       Date:  2022-07-08
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.